Tepotinib for gastric cancer – pro
On February 15, 2024, the Food and Drug Administration granted traditional approval to tepotinib (Tepmetko, EMD Serono, Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Pre-clincial studies suggst responsiveness of gastric cacner cells to this drug, but only a phase I study has been published, Shitara et al.
Sohn SH, Sul HJ, Kim BJ, Zang DY. Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44. Cancers (Basel). 2022 Jul 15;14(14):3444.
Sung-Hwa SohnHee Jung SulBum Jun KimDae Young Zang, Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44.
Dae Young Zang, Sung-Hwa Sohn, Hee Jung Sul, Bum Jun Kim, and Hyeong Su Kim, Responses to the MET inhibitor tepotinib in gastric cancers with MET amplification or both high PD-L1 expression and an MET exon 14 skipping mutation..July 2022Cancers 14(14):3444
Teponib Prescribing Information 2024